Peijia Medical logo

Peijia Medical(SEHK) 9996

Market CapHK$2.95BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-83%
5 Year-79%
1 Year-29%
1 Month-12%
HK$4.26
-2.63%
-0.11Today
Peijia Medical last closing stock price
MetricPriceDate
Last closeHKD 4.382026-10-14
Peijia Medical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-10.25%HKD 4.882026-10-07
1 month-11.52%HKD 4.952026-09-14
3 month-1.57%HKD 4.452026-07-16
Year to date-27.12%HKD 6.012025-12-31
1 year-28.55%HKD 6.132025-10-14
3 year-35.68%HKD 6.812023-10-13
5 year-78.53%HKD 20.402021-10-15
Since inception-82.97%HKD 25.802020-05-15

Peijia Medical Financials at a Glance

Market Cap

HK$2.95BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥1.45B

Net Income (TTM)

-CN¥366.18M

EPS (TTM)

-HK$0.23

P/E Ratio

-18.94

Dividend

HK$0.00

Beta (Volatility)

0.03 (Low)

Price

HK$4.26

Volume

256,000

Open

HK$4.26

Previous Close

HK$4.38

Daily Range

HK$4.05 - HK$4.30

52-Week Range

HK$3.73 - HK$7.37

Estimated Earnings Date

Apr 1, 2027

9996 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Peijia Medical

Peijia Medical Limited specializes in the innovation and development of advanced medical devices for transcatheter valve therapies and neurointerventional procedures. Founded in 2012 and headquartered in Suzhou, China, the company offers a diverse portfolio of products aimed at improving patient outcomes in the healthcare sector.

Products and Services
  • Transcatheter valve solutions, including TAVR systems like TaurusOne and TaurusElite
  • Neurointerventional devices such as Jasper and Presgo detachable coils
  • Complementary devices like TaurusAtlas transfemoral balloon catheter and TaurusExplora guidewire
Growth Outlook
  • Recent quarterly revenue of CNY 424.5 million shows a strong upward trend
  • Gross profit margin improved to 68.3% in the latest quarter
  • Investment in R&D reached CNY 82.5 million, indicating commitment to innovation
Financial Highlights
  • Trailing twelve months (TTM) revenue of CNY 1.4 billion reflects consistent growth
  • Operating income margin improved to 2.1% in the latest quarter
  • Cash and cash equivalents stood at CNY 810.97 million, providing liquidity
Peijia Medical Limited is positioned in the healthcare sector, focusing on advanced medical devices that cater to critical needs in transcatheter valve therapies and neurointerventional procedures. The company's diverse product offerings, including innovative TAVR systems and neurointerventional devices, highlight its commitment to enhancing patient care. Recent financial performance indicates a positive trajectory, with significant revenue growth and improved gross profit margins. The investment in research and development underscores the company's dedication to innovation, which is essential for maintaining a competitive edge in the medical device industry. With a solid cash position, Peijia Medical is well-equipped to navigate future challenges and capitalize on growth opportunities.
AI Generated • Oct 13, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

1,022

CEO

Yi Zhang, PhD

Website

www.peijiamedical.com

Headquarters

Suzhou, JS 215028, CN

9996 Financials

Key Financial Metrics (TTM)

Gross Margin

67.41%

Operating Margin

-15.49%

Net Income Margin

-17.98%

Return on Equity

-7.65%

Return on Capital

-8.72%

Return on Assets

-4.84%

Earnings Yield

-5.28%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

HK$2.95BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

674.85M

Volume

256.00K

Avg. Volume

707.54K

Financials (TTM)

Gross Profit

CN¥990.85M

Operating Income

-CN¥344.33M

EBITDA

-CN¥165.08M

Operating Cash Flow

CN¥57.00M

Capital Expenditure

-CN¥479.02M

Free Cash Flow

-CN¥422.02M

Cash & ST Invst.

CN¥766.57M

Total Debt

CN¥652.57M

Peijia Medical Performance Analysis

Peijia Medical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 291,688,22777.3%
20232023-12-31CNY 487,443,34767.1%
20242024-12-31CNY 667,321,34336.9%
20252025-12-31CNY 773,124,17515.9%
Peijia Medical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-314.3%
Q22025-06-3012.4%
Q42025-12-311.7%
Q22026-06-3018.1%
Peijia Medical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -0.70-32.6%
20232023-12-31CNY -0.64-9.4%
20242024-12-31CNY -0.37-42.5%
20252025-12-31CNY -0.33-9.7%
Peijia Medical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-140.0%
Q22025-06-3058.3%
Q42025-12-31-100.0%
Q22026-06-3094.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥424.50M

+40.9%

Gross Profit

CN¥290.04M

+32.5%

Gross Margin

68.32%

N/A

Market Cap

HK$2.95BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$2.86M

N/A

Employees

1,033

N/A

Net Income

-CN¥7.59M

+89.4%

EBITDA

CN¥72.47M

+219.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥766.57M

-17.5%

Total Debt

CN¥652.57M

+158.2%

Accounts Receivable

CN¥125.54M

+538.2%

Inventory

CN¥152.47M

-14.8%

Long Term Debt

CN¥262.29M

+19.5%

Short Term Debt

CN¥392.24M

+1082.4%

Return on Assets

-4.84%

N/A

Return on Invested Capital

-5.52%

N/A

Free Cash Flow

-CN¥11.95M

+88.2%

Operating Cash Flow

CN¥30.59M

+173.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,709.28-0.01%
^DJIDJI
$51,466.30-0.00%
^IXICNASDAQ
$26,684.28-0.02%
BTCBitcoin
$81,564.00-0.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$221.30-3.16%
BACBank of America
$51.39-4.76%
CRWVCoreWeave
$65.78-15.46%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$110.54-13.35%

Questions About 9996

What is the current price of Peijia Medical?

Peijia Medical is trading at HK$4.26 per share.

What is the 52-week range for Peijia Medical?

Over the past 52 weeks, Peijia Medical has traded between HK$3.73 and HK$7.37.

How much debt does Peijia Medical have?

As of the most recent reporting period, Peijia Medical reported total debt of CN¥494.57M.

How much cash does Peijia Medical have on hand?

Peijia Medical reported CN¥653.51M in cash and cash equivalents in its most recent financial results.

What is Peijia Medical’s dividend yield?

Peijia Medical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services